Equities Analysts Offer Predictions for Evolus Q4 Earnings

Key Points

• HC Wainwright raised Evolus’ Q4 2026 EPS estimate to $0.07 from $0.06, maintaining a Buy rating and $13 price target. It forecasts EPS of $0.20 in 2027 and $0.59 in 2028.
• Analyst sentiment is overall positive: MarketBeat reports a Moderate Buy consensus and a $15 average price target, with four Buy, one Hold, and one Sell rating.
• Insider David Moatazedi sold 105,108 shares at an average $9.04, reducing his holdings by 17.38%; he retained 499,592 shares after the sale.

Evolus, Inc. (NASDAQ:EOLS - Free Report) - Analysts at HC Wainwright increased their Q4 2026 EPS estimates for shares of Evolus in a research note issued on Thursday, November 5th. HC Wainwright analyst D. Tsao now expects that the company will earn $0.07 per share for the quarter, up from their prior estimate of $0.06. HC Wainwright currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for Evolus' current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Evolus' FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.59 EPS.

A number of other research firms have also recently weighed in on EOLS. Wall Street Zen raised shares of Evolus from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. BTIG Research increased their price target on shares of Evolus from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Thursday, November 5th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Evolus in a research note on Friday, September 11th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $15.00.

Evolus Stock Performance

NASDAQ:EOLS opened at $7.18 on Friday. The company has a 50-day moving average of $7.66 and a 200-day moving average of $6.35. Evolus has a 52 week low of $3.86 and a 52 week high of $9.31. The company has a market capitalization of $475.24 million, a price-to-earnings ratio of -15.28 and a beta of 1.38.

Insider Transactions at Evolus

In other Evolus news, insider David Moatazedi sold 105,108 shares of Evolus stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total transaction of $950,176.32. Following the completion of the transaction, the insider directly owned 499,592 shares of the company's stock, valued at approximately $4,516,311.68. This trade represents a 17.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 5.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Evolus

Large investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in Evolus by 65.6% during the 3rd quarter. GAMMA Investing LLC now owns 3,288 shares of the company's stock valued at $26,000 after purchasing an additional 1,303 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Evolus during the third quarter worth about $27,000. Legal & General Group Plc bought a new stake in Evolus during the second quarter worth about $40,000. Quantbot Technologies LP bought a new stake in Evolus during the second quarter worth about $56,000. Finally, Sequoia Financial Advisors LLC bought a new stake in Evolus during the second quarter worth about $71,000. Institutional investors own 90.69% of the company's stock.

About Evolus

Evolus, Inc. is a medical aesthetics company focused on developing and commercializing treatments for cosmetic procedures. The company's portfolio includes injectable products used by healthcare professionals to address facial lines and wrinkles and to enhance facial appearance. Its flagship product, Jeuveau (prabotulinumtoxinA-xvfs), is a prescription botulinum toxin treatment for moderate to severe frown lines between the eyebrows in adults. Evolus also markets Evolysse, a line of hyaluronic acid dermal fillers designed for facial aesthetic treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.